CYP19A1 and breast carcinoma: AIs such as anastrozole, letrozole, and exemestane are used commonly in breast cancer treatment to inhibit the CYP450 family aromatase, block the transformation of androgens secreted by peripheral tissues into estrogen [10], and reduce the systemic estrogen level of postmenopausal patients.